The U.S. Centers for Medicare & Medicaid Services indefinitely delayed the BALANCE pilot model after insurance plans did not commit to participate in covering obesity drugs under Medicare Part D. CMS extended the temporary Medicare GLP-1 Bridge demonstration through the end of 2027, while Medicaid BALANCE coverage remains active in participating states. The move effectively slows implementation of a policy designed to expand access to GLP-1-based obesity therapies for seniors, amid uncertainty around plan participation and financial implications. CMS’s decision keeps the market waiting on the operational details of how, and whether, Medicare will expand coverage. For drug developers and payers, the delay is a tangible reimbursement headwind because it limits near-term payer adoption at scale and prolongs cash-pay and alternative access models for patients. The policy trajectory also matters to biotech planning given how quickly pricing and formulary decisions can shift when Medicare coverage patterns change.